瑞舒伐他汀联合前列地尔治疗糖尿病肾病的临床研究  

Clinical study of Rosuvastatin combined with Alprostadil Injection in the treatment of diabetic nephropathy

作　　者：鞠富霞[1] 

机构地区：[1]临沂市沂水中心医院,山东沂水276400

出　　处：《药学研究》2015年第10期608-610,共3页Journal of Pharmaceutical Research

摘　　要：目的观察瑞舒伐他汀联合前列地尔治疗糖尿病肾病的临床疗效。方法 90例糖尿病肾病患者随机分为两组。前列地尔组45例,给予前列地尔注射液20μg,静脉滴注,每天1次;联合用药组45例,给予瑞舒伐他汀与前列地尔注射液,瑞舒伐他汀10 mg,口服,每天1次,前列地尔注射液用法同前组。两组疗程均为24周,观察两组治疗前后的尿蛋白排泄率、24 h尿蛋白、血肌酐、血脂等指标。结果治疗后,两组尿蛋白排泄率与24 h尿蛋白均降低(P<0.01)。联合用药组尿蛋白排泄率、24 h尿蛋白降低幅度大于前列地尔组(P<0.01),两组血肌酐与空腹血糖均下降,差异无显著意义(P>0.05)。两组血脂和血压降低均有所改善(P<0.01),联合用药组血脂改变程度优于前列地尔组(P<0.01)。结论瑞舒伐他汀联合前列地尔治疗糖尿病肾病,对肾脏保护有协同作用。Objective To observe the clinical efficacy of Rosuvastatin combined with Alprostadil Injection in the treatment of diabetic nephropathy. Methods Ninety patients were randomly divided into two groups: 45 patients of alprostadil group were treated with Alprostadil Injection 20 μg,qd; 45 patients in combination therapy group were treated with Rosuvastatin 10 mg,po,qd and Alprostadil Injection 20 μg,qd. All patients in each group received the correlative therapy for 24 weeks. The urinary albumin excretion rate( UAER),serum creatinine( Scr),blood lipid were observed and recorded before and after the treatment. Results After the treatment,UAER,24 h urine protein decreased in two groups( P < 0. 01). But the UAER,24 h urine protein decreased in combination therapy group which was better than those in alprostadil group( P <0. 01). The Scr and fasting blood glucose decreased in two groups with no significant difference among them( P > 0. 05).The blood lipid was improved in two groups( P < 0. 01),especially in combination therapy group. Conclusion Rosuvastatin and Alprostadil Injection in combination therapy were superior to monotherapy in the treatment of diabetic nephropathy.

关 键 词：糖尿病肾病 瑞舒伐他汀 前列地尔注射液 

分 类 号：R969.4[医药卫生—药理学]